ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021
Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic Efficacy of 11 SARS-CoV-2 Serological Assays for COVID-19: A Meta-Analysis and Adjusted Indirect Comparison of Diagnostic Test Accuracy.Immunity, inflammation and disease · 2024Pooled it
- A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Pooled it
- Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Comparative Evaluation of CLIA and ELISA Serological Assays for HSV-1 IgG With Western Blot Confirmation in a Clinical Cohort: A Cross-Sectional Study.Health science reports · 2026Article
- Consistent performance of cytomegalovirus IgG assays across platforms contrasts with marked IgM variability, supporting IgG avidity-based infection classification in a high-prevalence population.Scientific reports · 2026Article
- Accre 8 emerging point of care CLIA system for vitamin B12 assessment compared with three established assays.Scientific reports · 2025Article
- Unveiling the Quest: Crafting an Enzyme-Linked Immunosorbent Assay (ELISA) Technique to Uncover COVID-19 Antibodies.Cureus · 2024Review
- Clinical and Serological Findings of COVID-19 Participants in the Region of Makkah, Saudi Arabia.Diagnostics (Basel, Switzerland) · 2022Article
- Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay.Archives of Razi Institute · 2022Article
- Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.Translational lung cancer research · 2022Article
- Clinical evaluation of SARS-CoV-2 antigen-based rapid diagnostic test kit for detection of COVID-19 cases in Bangladesh.Heliyon · 2021Article
- Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Pathology, research and practice · 2021Review
- New infections and HIV-1 subtypes among febrile persons and blood donors in Oyo State, Nigeria.Journal of medical virology · 2021Article
- Effect of multiple freeze-thaw cycles on the detection of anti-SARS-CoV-2 IgG antibodies.Journal of medical microbiology · 2021Article
- Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population.Scientific reports · 2021Article
- Detection of Anti-Nucleocapsid Antibody in COVID-19 Patients in Bangladesh Is not Correlated with Previous Dengue Infection.Pathogens (Basel, Switzerland) · 2021Article
- Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits.Pathogens (Basel, Switzerland) · 2021Article
- Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals.Microorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate and compare the performances of five commercial ELISA assays (EDI, AnshLabs, Dia.Pro, NovaTec, and Lionex) for detecting anti-SARS-CoV-2 IgG.
methodsSeventy negative control samples (collected before the COVID-19 pandemic) and samples from 101 RT-PCR-confirmed SARS-CoV-2 patients (collected at different time points from symptom onset: ≤7, 8-14 and >14 days) were used to compare the sensitivity, specificity, agreement, and positive and negative predictive values of each assay with RT-PCR. A concordance assessment between the five assays was also conducted. Cross-reactivity with other HCoV, non-HCoV respiratory viruses, non-respiratory viruses, and nuclear antigens was investigated.
resultsLionex showed the highest specificity (98.6%; 95% CI 92.3-99.8), followed by EDI and Dia.Pro (97.1%; 95% CI 90.2-99.2), NovaTec (85.7%; 95% CI 75.7-92.1), then AnshLabs (75.7%; 95% CI 64.5-84.2). All ELISA kits cross-reacted with one anti-MERS IgG-positive sample, except Lionex. The sensitivity was low during the early stages of the disease but improved over time. After 14 days from symptom onset, Lionex and NovaTec showed the highest sensitivity at 87.9% (95% CI 72.7-95.2) and 86.4% (95% CI 78.5-91.7), respectively. The agreement with RT-PCR results based on Cohen's kappa was as follows: Lionex (0.89) > NovaTec (0.70) > Dia.Pro (0.69) > AnshLabs (0.63) > EDI (0.55).
conclusionThe Lionex and NovaLisa IgG ELISA kits, demonstrated the best overall performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.